About Biosergen
Biosergen is a company based in Solna (Sweden) founded in 2004. It operates as a HealthTech. Biosergen offers products and services including BSG005. Biosergen operates in a competitive market with competitors including Scynexis, F2g, Amplyx Pharmaceuticals, Elion Therapeutics and Viamet Pharmaceuticals, among others.
- Headquarter Solna, Sweden
- Stage Minicorn
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
- Legal Name Biosergen Ab
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
-
Investors
Rosetta Capital
& 1 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Biosergen
Biosergen offers a comprehensive portfolio of products and services, including BSG005. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
BSG005 is developed as an innovative antifungal treatment.
Funding Insights of Biosergen
- Total Funding Total Funding
- Total Rounds 2
- Last Round Last Round
- First Round First Round
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2016 | Amount | Grant - Biosergen | Valuation |
investors |
|
| Feb, 2013 | Amount | Private Equity Round - Biosergen | Valuation | Rosetta Capital , BtoV |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Biosergen
Biosergen has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Rosetta Capital and BtoV. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investment firm
|
Founded Year | Domain | Location | |
|
Stage agnostic VC firm funding companies in Europe
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Biosergen
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Biosergen
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Biosergen Comparisons
Competitors of Biosergen
Biosergen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Scynexis, F2g, Amplyx Pharmaceuticals, Elion Therapeutics and Viamet Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developing glucan synthase inhibitors for the treatment of fungal infections.
|
|
| domain | founded_year | HQ Location |
Drugs for systemic fungal diseases are discovered and developed.
|
|
| domain | founded_year | HQ Location |
Broad-spectrum fungal enzyme inhibitors are developed by clinical-stage biopharma.
|
|
| domain | founded_year | HQ Location |
Therapeutics for invasive fungal infections are developed by Elion Therapeutics.
|
|
| domain | founded_year | HQ Location |
Therapies for chronic fungal infections are developed using metalloenzyme inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Biosergen
Frequently Asked Questions about Biosergen
When was Biosergen founded?
Biosergen was founded in 2004 and raised its 1st funding round 9 years after it was founded.
Where is Biosergen located?
Biosergen is headquartered in Solna, Sweden.
Who is the current CEO of Biosergen?
Peder M Andersen is the current CEO of Biosergen.
What does Biosergen do?
Biosergen is engaged in the development of groundbreaking antifungal drugs, with a primary focus on their lead product, BSG005. This drug is designed to offer superior safety and potency for treating invasive fungal infections in immunocompromised patients, including those with AIDS, cancer, and transplant recipients. The company operates in the healthcare and biotechnology sector, providing solutions to address life-threatening fungal diseases recognized as a global health threat by WHO. Research and development are conducted in collaboration with institutions like the Norwegian University of Science and Technology and SINTEF in Norway, alongside global partnerships such as with Alkem Laboratories in India.
Who are the top competitors of Biosergen?
Biosergen's top competitors include Scynexis, F2g and Amplyx Pharmaceuticals.
What products or services does Biosergen offer?
Biosergen offers BSG005.
Who are Biosergen's investors?
Biosergen has 2 investors. Key investors include Rosetta Capital, and BtoV.
What is Biosergen's valuation?
The valuation of Biosergen is $9.44M as of Feb 2016.